Pandeia was acquired by a mid-cap pharmaceutical company in December 2022.Continued support for the GPR88 program as it reaches the clinic

Pandeia is developing first and best in class GPR88 agonists to treat the debilitating symptoms of Huntington’s disease. Co-founded and raised equity finance to build the company to a value inflection point

Based in Edinburgh and positioned to deploy the founders' world-leading expertise in phenotypic screening, stem cell technology and myelin biology, Pheno aims to discover and develop small molecule therapeutics that promote remyelination for a variety of unmet medical needs.

Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals.Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology.Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery.

Developing Bacterial Targeted RNA Therapeutics

Martin is a medicinal chemist with 20 years industrial experience in UK pharmaceutical companies ranging from start-up to medium sized. An established track record of innovation with over 50 scientific publications and >30 patent applications, many of which are granted. A particular focus in the design and exemplification of novel chemistry techniques and the identification of new drug candidates ready for clinical assessment. MAQU consulting can offer this medicinal chemistry expertise to enhance all aspects of pre-clinical drug discovery projects.

Mission Therapeutics are the world leading company in the field of deubiquitinase proteinase inhibition, an area of research that offers exciting opportunities for the discovery of new medicines for many diseases. I'm bringing in excess of 20years experience in the design and development of inhibitors of cysteinyl proteinases to compliment Mission's superb progress to date and accelerate development of their broad discovery pipeline.

Founded in 2004, Sygnature Discovery (www.sygnaturediscovery.com) is the UK’s largest independent provider of integrated drug discovery resource and expertise. The company adds value to clients’ research projects by providing advanced scientific knowledge and experience to accelerate hit identification and hit to lead and lead optimisation projects with core capabilities including medicinal chemistry, biosciences, computational chemistry, informatics and ADME/DMPK.

Established an internal Medicinal Chemistry team to provide creative and patentable new product ideas for Shire Speciality Pharma. Harnessed both internal and external expert networks to develop, refine and validate suitable project proposals with stakeholder buy-in for chemistry, DMPK, pharmacology, intellectual property and pre-clinical development plans. All practical work was outsourced, requiring identification of suitable CRO's to deliver molecules to appropriate timelines for follow-on secondary studies. Scientifically and functionally led multiple assigned small molecule programmes, advancing them expeditiously and cost-effectively through to key decision points.

Founding scientist of Incenta Ltd, a venture capital backed structure-based drug design company. Incenta combined advanced computational chemistry, combinatorial and medicinal chemistries, and biochemistry towards the generation and exemplification of proprietary, potent and selective compounds as drug candidates for the improvement of human health. Incenta Ltd was acquired by Amura Ltd in August 2002. Key achievements include;• Design and exemplification of the AMCoreTM scaffold, a new template for the inhibition of cysteinyl proteases. • LI and LO optimisation and proof-of-concept studies in key in vivo disease related models.• Assembly of pre-clinical safety portfolio for lead candidates.• Liaising with multiple CRO’s to secure synthetic, scientific and in vivo studies.• Planning and costing of regulatory pre-clinical and Phase I clinical studies. • Nomination of three candidates for GMP synthesis and regulatory safety assessment.• Organisation and prosecution of the intellectual property portfolio for the AMCoreTM scaffold and subsequent lead selection applications. Numerous patents have proceeded to grant.• Business development activities including investor presentations, organisation of CDA’s, MTA’s and licensing discussions.

Post-doc studies in the Sheppard group - where Fmoc solid phase synthesis of peptides was pioneered